Brookfield Asset Management Inc. Incyte Corp Transaction History

Brookfield Asset Management Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 16, 2022	BUY	$66.18 - $83.18 $4.08 Million - $5.12 Million	61,589 New	61,589 $4.68 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $1.91 Million - $2.41 Million	28,926 Added 88.56%	61,589 $0
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $218,526 - $263,840	-3,310 Reduced 9.2%	32,663 $0
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $2.28 Million - $2.67 Million	35,973 New	35,973 $0

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.